annual EBITDA:
-$106.88M+$24.91M(+18.90%)Summary
- As of today (June 23, 2025), TARS annual EBITDA is -$106.88 million, with the most recent change of +$24.91 million (+18.90%) on December 31, 2024.
- During the last 3 years, TARS annual EBITDA has fallen by -$93.42 million (-694.07%).
- TARS annual EBITDA is now -7823.05% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$22.59M-$2.08M(-10.14%)Summary
- As of today (June 23, 2025), TARS quarterly EBITDA is -$22.59 million, with the most recent change of -$2.08 million (-10.14%) on March 31, 2025.
- Over the past year, TARS quarterly EBITDA has increased by +$11.93 million (+34.56%).
- TARS quarterly EBITDA is now -309.56% below its all-time high of $10.78 million, reached on March 31, 2021.
Performance
TARS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$94.96M+$11.93M(+11.16%)Summary
- As of today (June 23, 2025), TARS TTM EBITDA is -$94.96 million, with the most recent change of +$11.93 million (+11.16%) on March 31, 2025.
- Over the past year, TARS TTM EBITDA has increased by +$48.69 million (+33.89%).
- TARS TTM EBITDA is now -15117.31% below its all-time high of -$624.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TARS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.9% | +34.6% | +33.9% |
| 3 y3 years | -694.1% | -13.6% | -119.9% |
| 5 y5 years | -2408.4% | -974.0% | -2404.1% |
TARS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -694.1% | +18.9% | -342.3% | +44.4% | -119.9% | +34.2% |
| 5 y | 5-year | -2408.4% | +18.9% | -309.6% | +44.4% | -2718.5% | +34.2% |
| alltime | all time | -7823.1% | +18.9% | -309.6% | +44.4% | <-9999.0% | +34.2% |
TARS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$22.59M(+10.1%) | -$94.96M(-11.2%) |
| Dec 2024 | -$106.88M(-18.9%) | -$20.51M(-1.5%) | -$106.88M(-15.8%) |
| Sep 2024 | - | -$20.82M(-32.9%) | -$126.97M(-12.0%) |
| Jun 2024 | - | -$31.04M(-10.1%) | -$144.23M(+0.4%) |
| Mar 2024 | - | -$34.51M(-15.0%) | -$143.64M(+9.0%) |
| Dec 2023 | -$131.79M(+120.7%) | -$40.60M(+6.6%) | -$131.79M(+26.7%) |
| Sep 2023 | - | -$38.08M(+25.0%) | -$104.03M(+18.5%) |
| Jun 2023 | - | -$30.45M(+34.4%) | -$87.79M(+40.6%) |
| Mar 2023 | - | -$22.66M(+76.5%) | -$62.44M(+4.7%) |
| Dec 2022 | -$59.70M | -$12.84M(-41.2%) | -$59.66M(-3.1%) |
| Sep 2022 | - | -$21.84M(+327.6%) | -$61.58M(+10.6%) |
| Jun 2022 | - | -$5.11M(-74.3%) | -$55.70M(+29.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$19.88M(+34.7%) | -$43.19M(+244.7%) |
| Dec 2021 | -$13.46M(-50.0%) | -$14.76M(-7.5%) | -$12.53M(+36.1%) |
| Sep 2021 | - | -$15.96M(-315.4%) | -$9.21M(+173.3%) |
| Jun 2021 | - | $7.41M(-31.3%) | -$3.37M(-76.0%) |
| Mar 2021 | - | $10.78M(-194.2%) | -$14.02M(-47.9%) |
| Dec 2020 | -$26.90M(+531.4%) | -$11.44M(+13.0%) | -$26.90M(+62.7%) |
| Sep 2020 | - | -$10.12M(+211.7%) | -$16.53M(+134.9%) |
| Jun 2020 | - | -$3.25M(+54.4%) | -$7.04M(+85.6%) |
| Mar 2020 | - | -$2.10M(+97.5%) | -$3.79M(+124.5%) |
| Dec 2019 | -$4.26M(+215.9%) | -$1.06M(+70.7%) | -$1.69M(+170.7%) |
| Sep 2019 | - | -$624.00K | -$624.00K |
| Dec 2018 | -$1.35M | - | - |
FAQ
- What is Tarsus Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals annual EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals TTM EBITDA year-on-year change?
What is Tarsus Pharmaceuticals annual EBITDA?
The current annual EBITDA of TARS is -$106.88M
What is the all time high annual EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high annual EBITDA is -$1.35M
What is Tarsus Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, TARS annual EBITDA has changed by +$24.91M (+18.90%)
What is Tarsus Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of TARS is -$22.59M
What is the all time high quarterly EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high quarterly EBITDA is $10.78M
What is Tarsus Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, TARS quarterly EBITDA has changed by +$11.93M (+34.56%)
What is Tarsus Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of TARS is -$94.96M
What is the all time high TTM EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high TTM EBITDA is -$624.00K
What is Tarsus Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, TARS TTM EBITDA has changed by +$48.69M (+33.89%)